Actinogen Medical

@ActinogenMed

Focused on the treatment of Alzheimer’s disease with lead candidate Xanamem™. ASX:

Vrijeme pridruživanja: listopad 2015.

Tweetovi

Blokirali ste korisnika/cu @ActinogenMed

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ActinogenMed

  1. 28. sij

    View our Quarterly Update Report & App 4C for 3 month 31 Dec 2019. “…We’re advancing the development of trial proposals to align with ’s strategic plans & expect a number of clinical studies to initiate during the year ahead” said

    Poništi
  2. 14. sij

    A great presentation at Sachs 3rd Annual Neuroscience Innovation Forum in San Francisco with Dr Bill Ketelbey providing a company update and latest Xanamem developments

    Poništi
  3. 13. sij

    We are delighted to be at . This is a great opportunity to update on latest developments. Xanamem has been demonstrated to be an efficacious, brain penetrant & appropriately safe oral drug, with clinical results in line with its intended mechanism of action.

    Poništi
  4. 10. sij

    & Week provides with an excellent opportunity to update the pharmaceutical industry & major global investors interested in Neuroscience on the compelling results achieved with XanaHES, & the expanded dataset generated during 2019.

    Poništi
  5. 8. sij

    is looking forward to present at and participate in partnering meetings during week in San Francisco. Contact info@actinogen.com.au if interested in meeting.

    Poništi
  6. proslijedio/la je Tweet
    27. pro 2019.

    Looking forward to hosting the Advances in Alzheimer’s & Other Cognitive Disorders Panel during our 3rd Annual Forum in San Francisco on 12th January 2020. Reserve your ticket now. More info at:

    Poništi
  7. proslijedio/la je Tweet
    27. pro 2019.

    Dr. Bill Ketelbey is a highly experienced and successful healthcare, biotech and pharmaceutical industry professional, with more than 30 years’ experience in the sector. Meet Bill at More info at:

    Poništi
  8. proslijedio/la je Tweet
    21. pro 2019.

    We're proud to include as the letter I this year! We featured interviews with two brilliant women in neuroscience, and Tamara Miller , which both proved to be very popular:

    Poništi
  9. 17. pro 2019.
    Poništi
  10. 16. pro 2019.

    Executive interview – Actinogen Medical CEO provides an update on recent developments, R&D progress and expected newsflow

    Poništi
  11. proslijedio/la je Tweet

    Great piece highlighting the trials and companies "giving ['s] patients hope of a better life” featuring and . Report by & . See here -

    Poništi
  12. 24. stu 2019.

    aims to treat by blocking excess stress hormone . “'s research is promising & in our recent XanaHES study, improved rapidly & persisted.” said . Watch tonight

    Poništi
  13. 19. stu 2019.

    Read more in our newsletter, for a company update & the great progress made with the development of & with our ongoing studies, on the back of recent outstandingly positive XanaHES results

    Poništi
  14. 7. stu 2019.

    Got 90 seconds? Listen to Actinogen Medical CEO Dr tell us about the latest exciting trial results and upcoming newsflow

    Poništi
  15. 5. stu 2019.

    Did you miss Investment Conference? Watch an update, with the path forward on next set of studies in , impairment in & & other therapeutic areas

    Poništi
  16. 31. lis 2019.

    Did you miss our presentation at ? Will Canty at speaks to to get an update on , the recent breakthrough results from the XanaHES trial and the exciting pathway forward

    Poništi
  17. proslijedio/la je Tweet
    30. lis 2019.

    CEO Will Canty speaks to , Managing Director of , at the 10th Annual Investment Conference to get an update of what has been up to. Watch the full interview through the link below.

    Poništi
  18. proslijedio/la je Tweet
    30. lis 2019.

    Bio-Link's will be representing at ’s annual conference, .

    Poništi
  19. 30. lis 2019.

    Our CEO is excited to be presenting at today. Come by Room 210/211 at 1345-1500 for a company update.

    Poništi
  20. proslijedio/la je Tweet
    29. lis 2019.

    Looking forward to this! Role play on derisking biotech messaging. and panel

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·